
Masahiro TORASAWA, MD. PhD.
@M_Torasawa • 3,188 subscribers
🇯🇵🫁Thoracic Medical Oncologist (@juntendo1838 / @NccriOfficial) | 🧬Genomics | 🎖️JLCS/JRS/IASLC Award Recipient | @harvardmed GCSRT Class of 2026
Videos

Witnessed the arrival of a potential game changer👀 #ASCO26 Plenary Session 🔥 RASolute 302 in RAS G12D–mutant pancreatic cancer Daraxonrasib showed a striking OS benefit vs chemotherapy: ✅ mOS 13.2 vs 6.6 months, HR 0.40 ✅ 12-mo OS 53.3% vs 18.7%
Masahiro TORASAWA, MD. PhD.12,773 görüntüleme • 1 ay önce
Daha fazla içerik yok.